The drug services firm Evotec has acquired Central Glass Germany from the Japanese chemical maker Central Glass for 1 € (99 cents). The deal includes a facility in Halle/Westphalia, Germany, with a staff of 60 and “significant” reactor capacity, Evotec says. The plant will support clinical- and commercial-scale manufacturing of small- molecule drugs for Evotec customers. Evotec intends to make the facility its European center for active pharmaceutical ingredients for rare diseases.
That's a flamin' hot deal, so there must be some kind of problem with the plant? Or there is a plant to be named later?